Viromed Medical AG, a German medical technology company specializing in cold plasma technology, published its half-year report for 2026 on September 28, showing advances in product development and market launch alongside a confirmed full-year guidance. The company, listed on the stock exchange since October 2022, reported consolidated revenue of EUR 2.5 million for the first half of 2026, up from EUR 2.4 million in the same period of 2025.
The net loss for the period widened to EUR 1.1 million from EUR 0.8 million in H1 2025, which the company attributed to expenses related to the comprehensive PulmoPlas® study and the approval and market launch of ViroCAP® med. Despite the loss, equity increased by 43.9% to EUR 9.5 million as of June 30, 2026, corresponding to an equity ratio of 67.6%, up from 39.9% a year earlier. The company financed itself primarily through a EUR 2.7 million loan from Perbamed Invest GmbH during the reporting period.
CEO Uwe Perbandt highlighted the company’s progress: “We successfully continued developing our products in the first half of the year while also making important progress in preclinical research. The planned publication of the study results in a renowned scientific journal will further strengthen the scientific evidence supporting our cold plasma technology.”
Operationally, Viromed advanced the preclinical development of PulmoPlas®, started OEM production of ViroCAP® for HELLMUT RUCK GmbH, and concluded an exclusive sales partnership with NEBU-TEC for veterinary applications of PulmoPlas®. The company also completed the conformity assessment procedure for ViroCAP® med as a Class IIa medical device under the EU Medical Device Regulation, receiving the official approval certificate in early July 2026, which enabled sales to begin. Additionally, Viromed was granted a research allowance of EUR 550,000 for research and development projects in cold plasma technology.
The planned acquisition of relyon plasma GmbH remained a key focus of strategic development. For the full 2026 financial year, Viromed expects a significant increase in consolidated revenue and net income, confirming the guidance adjusted on May 8, 2026. The half-year financial statements are available on the Viromed Medical AG website.
This news matters because it demonstrates Viromed’s transition from research and development to commercialization, with the market launch of ViroCAP® med and the expansion of sales partnerships potentially driving future revenue growth. The strengthened equity ratio and confirmed guidance provide a solid financial foundation, while the focus on cold plasma technology positions the company in a growing medical technology segment. Further details can be found on www.newmediawire.com.
